Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.

Chiara RapinesiGeorgios Demetrios KotzalidisLorenzo MazzariniRoberto BrugnoliStefano FerracutiSergio De FilippisIlaria CuomoGloria GiordanoAntonio Del CasaleGloria AngelettiGabriele SaniPaolo Girardi

Published in: Clinical drug investigation (2019)

Aripiprazole LAI may to be efficacious in reducing relapse of schizophrenia and bipolar disorder in the long term in stabilised patients and in improving symptoms of schizophrenia during its acute phase, with both monohydrate and lauroxil formulations showing efficacy.

Keyphrases

bipolar disorder
major depressive disorder
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
sleep quality
free survival